Our study found that the combination of abiraterone (Abi, the active component of abiraterone acetate in vivo) and RT increases the expression of CtBP-interacting protein (CtIP) in prostate cancer cells, and elevated CtIP levels in PCa are associated with poor prognosis. The gene discussed is RBBP8; the disease is prostate carcinoma.